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Autologous stem cell transplant (ASCT), is the 
treatment of choice for aggressive, 
relapsed/refractory Non- Hodgkin’s and Hodgkin’s 
Lymphomas [1, 2]. In patients aged less than 65 
years, 40-45% achieve cure with this form of 
treatment. The duration of remission post-transplant 
depends upon the histological subtype, prior 
treatment and the response to salvage therapy. In 
Pakistan, the common lymphomas for which patients 
receive treatment include: Diffuse Large B Cell 
Lymphoma (DLBCL), Mantle cell Lymphoma, 
Follicular Lymphoma and Hodgkin’s Lymphoma [3]. 
Of these, ASCT is commonly performed for DLBCL 
and Hodgkin’s Lymphoma in second complete 
remission [4]. 
Based on the opinion that ASCT can potentially cure 
50% of patients who relapse but are chemosensitive, 
this procedure was performed in a cohort of patients 
who partially responded to chemotherapy. Philip et al 
in 1998 [5] reported that 76% of the patients 
remained disease free with a six year survival of 75% 
post ASCT. The Non-Hodgkin’s Lymphoma 
Cooperative Study in 1993 showed a 5 year disease 
free survival of 36% (n=21 patients) [6]. This 
translated as a potential cure of approximately one in 
three patients with PR after ASCT. Hamdani M et al 
in 2014 [7], reported important outcomes on n=516 
DLBCL patients with respect to Rituximab based 
therapies and ASCT. The observations included:  a) 
patients receiving Rituximab based therapy and 
experiencing late relapse (> 1 year after treatment),  
have excellent response to ASCT; b) In patients with 
early relapse (within one year of treatment with 
Rituximab based regimens), ASCT can confer 
durable disease control; c) In patients who have 
refractory disease but respond to salvage therapies, 
ASCT is the only potentially curative treatment 
option; however a fourth observation included that a 
subset of patients relapsed within 6-9 months of 
transplant. This led to the inference of maintenance 
Rituximab. Gisselbrecht C et al in 2012 [8], after 
performing ASCT and randomly assigning patients to 
two groups of cohort (n=122 patients who received 
Rituximab, n=120 patients who did not receive 
Rituximab) concluded that there was no difference 
between the maintenance group and control group 
and did not recommend maintenance post-transplant. 
A study done by Zhang W et al [9] demonstrated that 
ASCT in combination with Rituximab in vivo 
purging followed by maintenance Rituximab 
prolongs progression free survival and overall 
survival. However this was a cohort of n=12 young 
patients with DLBCL. Therefore, the current 
recommendation for relapsed/refractory DLBCL 
remains to be ASCT in transplant eligible patients 
with no role of maintenance Rituximab.  
Most patients with Hodgkin’s Lymphoma (HL) 
achieve long term remission with chemo or 
radiotherapy. However, 10% - 30% of patients 
progress or relapse depending on the stage. ASCT 
can cure 50% of these patients.  In the remaining 
50%, treatment of HL remains to be a challenge 
[10,11]. The use of Brentuximab vedotin (anti-CD30) 
in early phase I trials did not demonstrate any clinical 
significance [12, 13]. Phase II trials however, 
demonstrated satisfactory results. The German 
Hodgkin Study Group showed an overall response 
rate (ORR) of 60% in n=45, heavily pretreated 
patients [14]. Due to this increased ORR and 
tolerable safety profile of the drug, FDA granted an 
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accelerated approval for the treatment of HL in 
patients who relapse after ASCT or in patients 
ineligible for transplant.  The National 
Comprehensive Cancer Network guideline includes 
Brentuximab for the same. Brentuximab has also 
been used as a bridge to ASCT in patients who fail 
standard and salvage treatments [15]. 
Moving forward, to further improve outcomes after 
ASCT in relapsed/refractory Lymphomas, efforts 
need to be focused on evaluating novel consolidation 
or maintenance strategies, possibly with agents not 
used in induction/salvage therapies. The current 
standard of care remains to be high dose 
chemotherapy followed by autologous stem cell 
transplant and immunotherapies cannot be used as an 
alternative to transplant. 
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